Use of strontium ranelate and risk of acute coronary syndrome: Cohort study

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1037-1043

  Svanström, Henrik ^a   Pasternak, Björn ^a   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; RISEDRONIC ACID; STRONTIUM RANELATE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MORTALITY; POSTMENOPAUSE; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASE; EPIDEMIOLOGY; OSTEOPOROSIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DENMARK; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROPORTIONAL HAZARDS MODELS; THIOPHENES;

EID: 84899895069     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205283     Document Type: Article

References (23)

1. O'Donnell S, Cranney A, Wells GA, et al. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006;(3): CD005326.
2. Pelletier JP, Roubille C, Raynauld JP, et al. Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Ann Rheum Dis 2013. Published Online First 2 Dec 2013. doi:10.1136/annrheumdis-2013-203989
3. European Medicines Agency. Recommendation to restrict the use of Protelos/Osseor (strontium ranelate). 26 April 2013. 2013. http://www.ema. europa.eu/ema/index. jsp?curl=pages/news-and-events/news/2013/04/news-detail- 001774. jsp&mid=WC0b01ac058004d5c1 (last accessed 16 Oct 2013).
4. European Medicines Agency. PRAC recommends suspending use of Protelos/Osseor (strontium ranelate). 10 January 2014. 2014. http://www.ema.europa.eu/docs/en- GB/document-library/Press-release/2014/01/ WC500159375.pdf (last accessed 23 Jan, 2014).
5. European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP). 20-23 January 2014. 2014. 24 January 2014. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/ 2014/01/news-detail-002009.jsp&mid=WC0b01ac058004d5c1 (last accessed 17 Feb, 2014).
6. Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 2014;25: 757-62.
7. Cooper C, Fox KM, Borer JS. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int 2014;25: 737-45.
8. Schneeweiss S, Gagne JJ, Glynn RJ, et al. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther 2011;90: 777-90.
9. Bolland MJ, Grey A, Avenell A, et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342.
10. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(7 Suppl): 22-5.
11. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39(7 Suppl): 38-41.
12. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39(7 Suppl): 30-3.
13. Helweg-Larsen K. The Danish Register of Causes of Death. Scand J Public Health 2011;39(7 Suppl): 26-9.
14. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;(1):CD004523.
15. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;(1):CD001155.
16. Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010;19: 858-68.
17. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87: 2060-6. (Pubitemid 34521489)
18. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350: 459-68. (Pubitemid 38133766)
19. Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: The randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002;13: 925-31. (Pubitemid 36050269)
20. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis-results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58: 1687-95. (Pubitemid 351847521)
21. Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013;98: 592-601.
22. Reginster JY, Chapurlat R, Christiansen C, et al. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled international trial. Osteoporos Int 2011;22:S742-3.
23. Donneau A-F, Reginster J-Y. Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporos Int 2014;25: 397-8.